In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transcatheter Technologies Aims To Fix EVAR Endoleaks

Executive Summary

Transcatheter Technologies GMBH is preparing to enter the $1.5-1.6 billion Endovascular Aortic Repair market with a product that it says offers advantages over devices that are already available.

You may also be interested in...



TAVR Market: Next-Generation Devices Seek To Optimize Outcomes

The market opportunity for TAVR is significant, with 2013 sales totaling $303.4 million in the US and $765 million outside the US, and those numbers are expected to grow to an estimated $1.29 billion and $1.63 billion, respectively, by 2018. Edwards and Medtronic dominate the worldwide market at present, but other companies are expected to make inroads with next-generation devices designed to optimize outcomes.

EVAR Update: Competitors Stake Their Ground In A High-Growth Space

The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.

Transcatheter Technologies GMBH

A major limitation of existing transcatheter aortic heart valves is that they are unable to be repositioned once implanted. For these devices, the valve is mounted in a metal stent that contains a balloon, which is inflated once the valve is placed. The valve is then anchored to the heart wall. Transcatheter Technologies GMBH believes its fully repositionable Trinity valve will solve this shortcoming. Once Trinity is initially placed, cardiac surgeons or interventionalists can evaluate the valve function to determine whether the valve needs to be repositioned, retrieved or kept in the same position. Moreover, it allows for a controlled positioning, by slowly opening the valve stent, for a likely first-attempt correct placement.

Topics

Related Companies

UsernamePublicRestriction

Register

RS150180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel